{
    "nctId": "NCT00372710",
    "briefTitle": "Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions",
    "officialTitle": "Efficacy and Tolerability of Intravenous Zoledronic Acid 4mg as an Adjunct to Standard Therapies Including Conversion From Pamidronate in Breast Cancer Patients With Metastatic Bone Lesions. A Prospective, Randomised, Open-label, Clinical Study",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer With Bone Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Efficacy of a switch over from pamidronate therapy (2 infusions) to a treatment with zoledronic acid 4mg every 4 weeks (10 infusions) for 44 weeks in patients with breast cancer-related bone lesions",
    "eligibilityCriteria": "Inclusion criteria\n\n* Confirmed diagnosis of Breast Cancer with at least one breast cancer-related bone lesion\n* No treatment with bisphosphonates within 6 months prior to inclusion into the study\n* Good health status (ECOG Performance status 0-2)\n\nExclusion criteria\n\n* Patients who do not have at least one breast cancer-related bone lesion that is detectable on conventional radiographs of bone (plain film) at screening\n* Abnormal renal function\n* History of diseases with influence on bone metabolism such as Paget's disease and primary hyperparathyroidism\n* Pregnancy and lactation\n* Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures, recent (within 6 weeks) or planned dental or jaw surgery (e.g..extraction, implants)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}